KR20230024079A - Micrococcus antarcticus strain and its use for improving skin conditions - Google Patents

Abstract

The present invention relates to: a novel Micrococcus antarcticus MC-1 strain; a lysate, a culture solution, and an extract thereof; a composition containing the same; and a use thereof for improving skin conditions. The novel Micrococcus antarcticus strain according to one aspect has effects of preventing skin aging, reducing skin wrinkles, alleviating skin inflammation, alleviating atopy, and suppressing itching, and thus can be applied in a variety of ways for skin condition improvement, prevention, or treatment.

Description

Micrococcus antarcticus strain and its use for improving skin conditions

It relates to novel microorganisms, their lysates, cultures, extracts, and uses for improving skin conditions.

The ecosystem of the skin provides various types of habitats for microorganisms, and a wide range of microorganisms live there. The human host forms a symbiotic relationship with them, and they are known to have many positive effects on the host. The skin constitutes various types of habitats, such as indentations and specialized crevices, and helps a wide range of microorganisms to grow. Basically, the skin forms a physical barrier and helps to defend against potential risk factors and toxic substances from the outside. The skin becomes a point of contact with the external environment and is also a gathering place for various microorganisms (fungi, bacteria, viruses, and small larvae). According to the selection of physical and chemical functions, microorganisms adapt to specialized niches to prepare habitats. In general, the skin is cold, has an acidic nature, and remains dry. Structurally, the epidermis forms the skin barrier, blocks the penetration of microorganisms and toxins, and plays an important role in retaining moisture. The uppermost layer of the epidermis is composed of the stratum corneum. The epidermis has a form called 'brick and mortar structure', and the skin tissue undergoes a continuous self-healing process, and the scales that have passed through the differentiation process are constantly eliminated from the skin tissue.

Probiotics is a collective term for microorganisms that have a beneficial effect on the human body, and refers to microorganisms that benefit the body. Most probiotics known to date are known as lactic acid bacteria. Probiotics have been reported to produce effective effects through various beneficial actions on the human body, but studies on the interaction between skin flora and skin are insufficient.

Accordingly, there is a need to develop dermatophytes that can be usefully used for skin-related conditions.

One aspect is to provide novel Micrococcus antarcticus strains.

Another aspect is to provide a lysate of the strain, a culture medium, or an extract of the culture medium.

Another aspect is to provide a composition comprising an extract of the Micrococcus antarcticus strain, its lysate, culture medium, or culture medium.

Another aspect provides a method for preventing, ameliorating, or treating a condition in a subject in need thereof comprising administering to a subject in need thereof an effective amount of a composition described above.

One aspect provides Micrococcus antarcticus strains.

The strain may be isolated. In this specification, the term “isolated” means something that is artificially separated and available that does not exist in nature. The strain may be isolated from human skin. The strain may be isolated from human keratinocytes. The strain may be a strain isolated by a method of inoculating human keratinocytes into R2A (Reasoner's 2A) medium (Becton Dickinson, Cockeysville, MD) and culturing the cultured colony in pure isolation.

The strain may be a strain belonging to the Micrococcus sp .

The strain comprises a 16S rRNA having at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity with SEQ ID NO: 1 it may be The strain may contain the 16S rRNA of SEQ ID NO: 1.

As used herein, the term "sequence identity" refers to the degree of identity of amino acid residues or bases between sequences after aligning both sequences in a specific comparison region so as to match each other as much as possible. Sequence identity can be confirmed according to methods known in the art. The percent of sequence identity can be determined using a known sequence comparison program, examples of which include BLASTN (NCBI), CLC Main Workbench (CLC bio), MegAlign™ (DNASTAR Inc), and the like.

The Micrococcus antarcticus ( Micrococcus antarcticus ) The strain may be a strain deposited with accession number KCCM12995P. The strain deposited with the accession number may be Micrococcus antarcticus MC-1 strain.

The strain may have a skin condition improving effect. For example, the skin condition improvement may be one or more of skin aging prevention, skin wrinkle improvement, skin inflammation improvement, atopy improvement, and itching inhibition.

Another aspect provides a lysate of the strain, a culture medium, or an extract of the culture medium.

Details of the strain are as described above.

In this specification, the term "lysate" may be used interchangeably with "lysate" and may refer to a product obtained by disrupting the cell wall of a strain by chemical or physical force. The homogenate may include the homogenate itself, a concentrate or a lyophilized product thereof.

As used herein, the term "culture medium" may be used interchangeably with "culture supernatant", "conditioned culture medium" or "conditioned medium", and provides nutrients for Micrococcus antarcticus strains to grow and survive in vitro. It may mean the entire medium including the strain obtained by culturing the strain for a certain period of time in a medium capable of supplying the strain, its metabolites, and extra nutrients. In addition, the culture solution may mean a culture solution obtained by removing the cells from the cell culture solution obtained by culturing the strain. On the other hand, the liquid from which the cells are removed from the culture solution is also called "supernatant", and the culture solution is left still for a certain period of time to take only the liquid of the upper layer except for the part sunk in the lower layer, remove the cells through filtration, or centrifuge the culture solution to It can be obtained by removing the precipitate and taking only the upper liquid. The "cell" refers to the strain itself of the present invention, and includes the strain itself isolated and selected from a sample or the strain isolated from the culture solution by culturing the strain. The cells can be obtained by centrifuging the culture solution and taking the part that has sunk to the lower layer, or it can be obtained by leaving it for a certain period of time and then removing the upper liquid because it sinks to the lower layer of the culture medium by gravity.

The culture solution may include the culture solution itself obtained by culturing the strain, its concentrate or lyophilisate, or the culture supernatant obtained by removing the strain from the culture solution, its concentrate or lyophilisate.

A culture medium and culture conditions for culturing the Micrococcus antarcticus strain may be appropriately selected or modified by those skilled in the art. For example, the culture medium obtained by culturing in a medium (eg, R2A medium, RCM medium or TSA medium) at a temperature above 10 ° C or below 40 ° C for a certain period of time, for example, 4 to 50 hours it could be

As used herein, the term "culture broth extract" refers to an extract obtained from the culture medium or a concentrate thereof, and may include an extract, a dilution or concentrate of the extract, a dried product obtained by drying the extract, or a crude or purified product thereof, or a fraction obtained by fractionating the same. can

The strain, a lysate thereof, a culture medium, or an extract of the culture medium may be biologically pure. The strain may be obtained by pure culture.

Another aspect provides the use of a Micrococcus antarcticus strain, a lysate, culture, or extract of the strain. Specifically, it provides a composition comprising a Micrococcus antarcticus strain, a lysate thereof, a culture medium, or an extract of the culture medium.

In the use or composition, the Micrococcus antarcticus strain may be the Micrococcus antarcticus strain according to the above aspect. In one embodiment, the strain may be isolated from human skin. In other embodiments, the strain has at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.5%, or at least about 99.9% sequence identity with SEQ ID NO: 1 It may include 16S rRNA having In another embodiment, the strain may be one containing the 16S rRNA of SEQ ID NO: 1. In another embodiment, the strain may be a strain deposited with accession number KCCM12995P.

The use of the strain may include improving skin conditions, improving skin beauty, and preventing, improving or treating skin diseases.

The skin condition improvement or skin beauty improvement may be one or more of skin aging prevention, skin wrinkle improvement, skin inflammation improvement, atopy improvement, and itching inhibition.

This strain increases COL1A1 expression; decrease MMP-1 expression; It may be to reduce IL-6 expression.

As used herein, the term "skin aging" refers to both tangible and intangible changes that appear in the skin with age, such as thinning of the epidermis, decrease in the number of cells or blood vessels in the dermis, decrease in DNA damage repair ability, cell replacement Cycle reduction, wound healing ability, skin barrier function, epidermal moisture retention function, vitamin D production, physical damage defense function, chemical substance removal ability, immune response, sensory function, body temperature control, etc. says

The skin aging may be caused by extrinsic factors or endogenous factors. The extrinsic factor refers to various external factors, such as ultraviolet rays (light), and the endogenous factor is also referred to as a chronological factor and refers to a factor mainly caused by the passage of time. That is, the skin aging is not only premature aging symptoms induced by external stimuli such as ultraviolet rays, pollution, cigarette smoke, chemicals, etc., but also a natural aging phenomenon that occurs as the proliferation of skin cells decreases with age. It is a concept that includes wrinkles, loss of elasticity, skin sagging and dryness. In addition, wrinkles include stimulation caused by changes in internal and external factors that cause wrinkles by changing components constituting skin tissue.

The aging may be photoaging. The term "photoaging" is a phenomenon caused by external environmental factors, and the most representative factor is ultraviolet rays. Ultraviolet rays cause damage to biocomponents such as activation of proteolytic enzymes, chain scission of matrix proteins, and abnormal cross-linking, and repetition of these mechanisms results in apparent skin aging.

In this specification, the term "wrinkle" refers to a state in which elasticity of the skin is lost and loosened, and for example, the skin may be folded. The "prevention or improvement of skin wrinkles" may mean any action of preventing or improving wrinkles by suppressing the expression of wrinkle-related factors or increasing the total amount of collagen.

In the present specification, the term "improvement of inflammation" may be used interchangeably with "inhibition of inflammation" and "anti-inflammation", and may refer to any action in which NO production is suppressed by alleviating the immune response.

As used herein, the term "skin disease" may be a disease or skin inflammation due to skin barrier function impairment. As used herein, the term "prevention" includes inhibiting the occurrence of a disease. As used herein, the term "treatment" includes the inhibition, alleviation, or elimination of the development of a disease.

The skin inflammatory disease may be any one selected from the group consisting of dermatitis, atopic dermatitis, pruritus (pruritus), eczematous skin disease, dry eczema, erythema, urticaria, psoriasis, drug rash, and acne.

The composition according to one aspect increases the expression of COL1A1 or reduces the expression of MMP-1 by including the Micrococcus antarcticus strain, its lysate, culture medium or an extract of the culture medium, thereby preventing skin aging and improving skin wrinkles. effect can be shown.

The composition according to one aspect reduces the expression of inflammatory cytokines (eg, IL-6) by including the Micrococcus antarcticus strain, a lysate thereof, a culture medium or an extract of the culture medium, thereby improving skin inflammation, or skin inflammation Disease, atopy, skin disease prevention, improvement or treatment effects such as itching can be shown.

In another embodiment, the strain may exhibit a synergistic effect when used together with other strains having a skin condition improving effect, for example, a strain belonging to the genus Micrococcus.

The composition is 0.001% to 80% by weight, for example, 0.01% to 60% by weight, 0.01% to 40% by weight, 0.01% to 30% by weight, 0.01% to 20% by weight, based on the total weight of the composition. %, 0.01% to 10%, 0.01% to 5%, 0.05% to 60%, 0.05% to 40%, 0.05% to 30%, 0.05% to 20%, 0.05% to 10% by weight, 0.05% to 5% by weight, 0.1% to 60% by weight, 0.1% to 40% by weight, 0.1% to 30% by weight, 0.1% to 20% by weight, 0.1% by weight % to 10% by weight, or 0.1% to 5% by weight of the strain, a lysate thereof, a culture medium, or an extract of the culture medium.

As used herein, the term "included as an active ingredient" means that the strain of the present specification, its lysate, culture medium, or extract of the culture medium is added to the extent that the above-mentioned effects can be exhibited, and drug delivery and stabilization, etc. It means that it is formulated in various forms by adding various components as subcomponents for the purpose.

The composition may be in a liquid or dry state. In one embodiment, the composition may be in the form of a dry powder.

A drying method for preparing the composition in a dry state may use a method commonly used in the art, and is not particularly limited. Non-limiting examples of the drying method include an air drying method, a natural drying method, a spray drying method, a freeze drying method, and the like. These methods may be used alone or at least two methods may be used together.

The composition may contain an additive in an effective amount sufficient to reduce deterioration of the strain, its lysate, culture medium or extract of the culture medium. The additive may be, for example, a binder, but is not limited thereto.

The composition may further include a cosmetically, pharmaceutically or food-acceptable carrier. The composition may be formulated with a carrier and provided as cosmetics, drugs, food additives, and the like.

The composition may be a cosmetic composition.

The cosmetic composition may further include ingredients commonly used in cosmetic compositions, functional additives, etc. in addition to the active ingredients disclosed herein, such as antioxidants, stabilizers, solubilizers, surfactants, dispersants, emulsifiers, and preservatives. , conventional adjuvants such as vitamins, pigments, flavors, and the like, and carriers.

The cosmetic composition is not particularly limited to a specific formulation, and the formulation may be appropriately selected according to the purpose. The cosmetic composition may have, for example, a solubilizing formulation, an emulsifying formulation, or a dispersion formulation. The cosmetic composition may have, for example, a softening lotion, a nutrient lotion, a massage cream, a nutrient cream, an essence, a pack, a gel, an ampoule, or a skin-adhesive cosmetic formulation.

The composition may be a composition for external application for skin.

In the present specification, the external skin preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal delivery patch, drug-containing bandage, lotion, or a combination thereof. The external skin preparation is a component usually used in external preparations for skin such as cosmetics or pharmaceuticals, for example, water-based components, oil-based components, powder components, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, and fragrances. , colorants, various skin nutrients, or combinations thereof and may be suitably blended as needed. The skin external preparation, metal sequestering agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid; drugs such as caffeine, tannin, bellapamil, licorice extract, glabridin, hot water extract of calin fruit, various herbal medicines, tocopherol acetate, glycylitnic acid, tranexamic acid and its derivatives or salts; Vitamin C, magnesium ascorbyl phosphate, ascorbic acid glucoside, arbutin, kojic acid; Sugars, such as glucose, fructose, and trehalose, etc. can also be mix|blended suitably.

The composition may be a pharmaceutical composition.

The pharmaceutical composition may additionally include a pharmaceutically acceptable diluent or carrier. The diluent may be lactose, corn starch, soybean oil, microcrystalline cellulose, mannitol, or a combination thereof. The carrier may be an excipient, a disintegrant, a binder, a lubricant, or a combination thereof. The excipient may be microcrystalline cellulose, lactose, low-substituted hydroxycellulose, or a combination thereof. The disintegrant may be calcium carboxymethylcellulose, sodium starch glycolate, calcium monohydrogen phosphate, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.

The pharmaceutical composition may be formulated for oral or parenteral administration. Oral dosage forms may be granules, powders, liquids, tablets, capsules, dry syrups, and the like. Parenteral dosage forms may be injections, ointments, and the like.

The composition may be a health functional food composition. In this case, it may be formulated in the form of a conventional health functional food known in the art.

The health functional food composition may be used alone, or in combination with other foods or food ingredients, and may be appropriately used according to conventional methods. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment). There is no particular limitation on the type of health functional food. Among the types of health functional foods, beverage compositions may contain various flavoring agents or natural carbohydrates as additional components, like conventional beverages. The natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; and polysaccharides such as dextrins and cyclodextrins; It is a sugar alcohol, such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as thaumatin and stevia extract, or synthetic sweeteners such as saccharin and aspartame may be used. The food composition is also used in nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonated beverages carbonation agent, or a combination thereof. The food composition may also contain natural fruit juice, fruit juice beverages, fruit flesh for preparing vegetable beverages, or a combination thereof.

Another aspect provides a method for preventing, ameliorating, or treating a condition in a subject in need thereof comprising administering to a subject in need thereof an effective amount of a composition described above.

The condition of the subject may be a condition related to skin or a condition related to skin inflammation.

The terms "administering," "introducing," and "implanting" are used interchangeably herein, and according to one embodiment, a subject by a method or route that results in at least partial localization of a composition to a desired site. It can mean the placement of a composition according to one embodiment into.

Administration may be administered by a method known in the art. Administration may be administered directly to a subject by any means, for example, by routes such as intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration. can The administration may be administered systemically or locally.

The subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat, or cat. The subject may be a subject in need of skin improvement, for example, a subject in need of anti-aging of the skin, improvement of skin wrinkles, improvement of skin inflammation, improvement of atopy, or anti-itch effect.

The administration is 0.1 mg to 1,000 mg per day of the composition according to one embodiment, for example, 0.1 mg to 500 mg, 0.1 mg to 100 mg, 0.1 mg to 50 mg, 0.1 mg to 25 mg, 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg to 50 mg , 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg may be administered. However, the dosage may be prescribed in various ways depending on factors such as formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity, and those skilled in the art can Dosage can be appropriately adjusted in consideration of these factors. The number of administrations can be once a day or two or more times within the range of clinically acceptable side effects, and administration can be performed at one or two or more sites, daily or at intervals of 2 to 5 days. The number of administration days may be administered from 1 day to 30 days per treatment. If necessary, the same treatment can be repeated after a titration period. For non-human animals, the same dosage per kg as for humans is used, or the above dosage is converted by the volume ratio (eg, average value) of the organ (heart, etc.) between the target animal and the human. A single dose can be administered.

According to the novel Micrococcus antarcticus strain according to one aspect, since it has effects of preventing skin aging, improving skin wrinkles, improving skin inflammation, improving atopy, and inhibiting itching, it can be applied in various ways for skin improvement, prevention, or treatment. can

1 is a result showing the relative expression level of COL1A1 in fibroblasts.
2 is a result showing the relative expression level of MMP-1 in fibroblasts.
3 is a result showing the relative expression level of IL-6 in keratinocytes.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are intended to illustrate the present invention by way of example, and the scope of the present invention is not limited to these examples.

Example 1. Isolation and identification of strains

Micrococcus antarcticus strains were isolated and identified from the skin of healthy women.

Specifically, samples obtained by washing the skin of healthy women with sterile distilled water, that is, human epidermal keratinocytes, were inoculated into R2A (Reasoner's 2A) medium (Becton Dickinson, Cockeysville, MD). After inoculation, 100 colonies formed after culturing in an incubator at 28° C. for 48 hours were cultured in pure isolation and re-cultured in an incubator at 28° C. for 48 hours.

The cultured colony was subjected to 16S rRNA gene sequence identification. Specifically, PCR was performed using primers designed to amplify in response to bacteria only. PCR amplification was carried out in 30 cycles of 95 ° C for 1 minute, 55 ° C for 1 minute, and 75 ° C for 1 minute and 30 seconds, and finally treated at 72 ° C for 8 minutes and stored at 4 ° C. After the PCR reaction, the DNA sequences of the isolated and cultured species were determined using ABI-3730XL (ABI, USA).

Homology 99 when the nucleotide sequence of the 16S rRNA region determined in the isolated and cultured microbial colony was compared and analyzed with other strains registered using the BLAST program provided on the website of the National Center for Biotechnology Information (NCBI). A new microorganism Micrococcus antarcticus strain (hereinafter referred to as "MC-1") of less than % was selected. The selected MC-1 strain was deposited with the Korea Microorganism Conservation Center (KCCM) on May 28, 2021 and was given accession number KCCM12995P. The MC-1 strain has a 16S rRNA sequence of SEQ ID NO: 1 (complementary DNA).

Experimental Example 1. Analysis of anti-aging and anti-wrinkle activity - COL1A1 expression increase, MMP-1 expression decrease confirmed

In order to analyze the effect of the culture solution of the MC-1 strain isolated in Example 1 on factors related to skin aging and wrinkle formation in aged skin by ultraviolet (UV) irradiation, COL1A1 (Collagen, type I, alpha 1) And expression of MMP-1 (Matrix metalloproteinase-1) was confirmed.

Specifically, human dermal fibroblast cell line (Human dermal fibroblast, Hs68) was divided into 3.5x10 ⁵ in a 6-well plate, and then cultured for 24 hours in an incubator at 37°C and 5% CO ₂ conditions. Thereafter, the medium was removed, DPBS (Dulbecco's phosphate-buffered saline) was added, and 12 mJ/cm ² of UVB was irradiated or not irradiated. Immediately after UVB irradiation, DPBS was removed and replaced with FBS-free medium, and then treated with 1% (w/w) of the culture medium of the MC-1 strain and further cultured for 24 hours. As a negative control group, UV treatment and strain culture solution non-treatment groups were used.

After that, RNA was isolated from the cells of each sample using Trizol (RNA iso, DAKARA, Japan), RNA was quantified at 260 nm with a nanodrop, and then 2 μg of RNA was used in an amplifier. cDNA was synthesized (C1000 Thermal Cycler, Bio-Rad, USA). Using the synthesized cDNA as a template, cybergreen (SYBR Green supermix, Applied Biosystems, USA) was added together with primers and cDNA for the target genes COL1A1 and MMP-1, and a real-time PCR machine (Step One Plus, Applied Biosystems, USA) was used. Real-time polymerase chain reaction was performed at Biosystems, USA). The expression level of the gene was finally analyzed through correction for the β-actin gene, and the results are shown in FIGS. 1 and 2.

As shown in Figure 1, it was confirmed that the MC-1 strain significantly increased the expression of COL1A1, which was reduced by UV light.

As shown in Figure 2, it was confirmed that the MC-1 strain significantly reduced the expression of MMP-1 increased by UV light.

These results mean that the MC-1 strain is effective in preventing skin aging (eg, photoaging) and improving skin wrinkles.

Experimental Example 2. Analysis of anti-inflammatory, anti-atopic and anti-itching activities - confirmation of IL-6 expression reduction

In order to analyze whether the culture solution of the MC-1 strain isolated in Example 1 has anti-inflammatory, anti-atopic and anti-itching activities, the expression of the inflammatory cytokine IL-6 was confirmed.

Specifically, human keratinocyte HaCaT cells were cultured in DMEM medium (Dulbecco's modified Eagle's Medium, Gibco 1210-0038) containing 10% fetal bovin serum. % CO ₂ was performed in an incubator. The medium was exchanged every 3 to 4 days, and subculture was performed when the cells proliferated excessively. Thereafter, the cells were dispensed at 5×10 ⁵ /well and washed with phosphate buffered saline solution (PBS) after 24 hours of culture. Cells were seeded into each well containing DMEM medium without FBS, and inflammation was induced in the keratinocyte cell line by adding 10 μg/ml of Poly I:C and 10 ng/ml of IL-4. Next, the culture medium of the above strain was treated at a concentration of 1% (w/w), and further cultured for 4 hours. As a positive control group, 1 μM of dexamethasone was used. The expression level of IL-6 was analyzed in the same manner as in Experimental Example 1, except that the IL-6 primer was used. The expression level of the gene was finally analyzed through correction for the β-actin gene, and the results are shown in FIG. 3 .

As shown in Figure 3, it was confirmed that the MC-1 strain significantly reduced the expression of IL-6, an inflammatory cytokine, compared to the untreated control group.

These results mean that the MC-1 strain can be usefully used for the prevention, improvement, or treatment of skin inflammatory diseases, atopy, and itching.

Taken together, the Micrococcus antarcticus MC-1 strain increased COL1A1 expression and decreased MMP-1 expression; It was confirmed that IL-6 expression was reduced. Accordingly, it was found that the Micrococcus antarcticus MC-1 strain had effects of preventing skin aging, improving skin wrinkles, improving skin inflammation, improving atopy, and inhibiting skin itching.

The above description is merely an example of the technical idea of the present invention, and various modifications and variations can be made to those skilled in the art without departing from the essential characteristics of the present invention.

Korea Microbial Conservation Center (Overseas) KCCM12995P 20210528

SEQUENCE LISTING <110> Cosmax, INC. <120> Micrococcus antarcticus strain and its use for improving skin conditions <130> PN139629 <160> 1 <170> PatentIn version 3.2 <210> 1 <211> 1322 <212> DNA <213> Micrococcus antarcticus <400> 1 aggatgaacg ctggcggcgt gcttaacaca tgcaagtcga acgatgaagc ccagcttgct 60 gggtggatta gtggcgaacg ggtgagtaac acgtgagtaa cctgcccttg actctaggat 120 aagcccggga aactgggtct aatactggat aggaacgtct accgcatggt ggatgttgga 180 aagaatttcg gtcatggatg gactcgcggc ctatcagctt gttggtgagg taatggctca 240 ccaaggcgac gacgggtagc cggcctgaga gggtgaccgg ccacactggg actgagacac 300 ggcccagact cctacggggg gcagcagtgg ggaatattgc acaatgggcg aaagcctgat 360 gcagcgacgc cgcgtgaggg atgacggcct tcgggttgta aacctctttc agtagggaag 420 aagcgaaagt gacggtacct gcagaagaag caccggctaa ctacgtgcca gcagccgcgg 480 taatacgtag ggtgcgagcg ttatccggaa ttatattgggcg taaagagctc gtaggcggtt 540 tgtcgcgtct gtcgtgaaag tccggggctt aaccccggat ctgcggtggg tacgggcaga 600 ctagagtgca gtagggggaga ctggaattcc tggtgtagcg gtggaatgcg cagatatcag 660 gaggaacacc gatggcgaag gcaggtctct gggctgtaac tgacgctgag gagcgaaagc 720 atggggagcg aacaggatta gataccctgg tagtccatgc cgtaaacgtt gggcactagg 780 tgtggggaac attccacgtt ttccgcgccg cagctaacgc attaagtgcc ccgcctgggg 840 agtacggccg caaggctaaa actcaaagga attgacgggg gcccgcacaa gcggcggagc 900 atgcggatta attcgatgca acgcgaagaa cctaccaag gcttgacatg ttctcgatcg 960 ccgtagagat acggtttccc ctttggggcg ggttcacagg tggtgcatgg ttgtcgtcag 1020 ctcgtgtcgt gagatgttgg gttaagtccc gcaacgagcg caaccctcgt tccatgttgc 1080 cagcacttcg ggtggggact catgggagac tgccggggtc aactcggagg aaggtggggga 1140 cgacgtcaaa tcatcatgcc ccttatgtct tgggcttcac gcatgctaca atggccggta 1200 caatgggttg cgatactgtg aggtggagct aatcccaaaa agccggtctc agttcggatt 1260 ggggtctgca actcgacccc atgaagtcgg agtcgctagt aatcgcagat cagcaacgct 1320 GC 1322

Claims (9)

A Micrococcus antarcticus strain comprising a 16S rRNA having 95% or more sequence identity with SEQ ID NO: 1. The method according to claim 1, the strain deposited with accession number KCCM12995P. A culture solution of the strain of claim 1. A cosmetic composition comprising the strain of claim 1, a lysate thereof, a culture medium, or an extract of the culture medium. The cosmetic composition according to claim 4, which is for improving skin condition. The cosmetic composition according to claim 5, wherein the improvement of skin condition is at least one of anti-aging of skin, improvement of skin wrinkles, improvement of skin inflammation, improvement of atopy, and inhibition of itching. The method of claim 5 , which increases COL1A1 expression; decrease MMP-1 expression; A cosmetic composition that reduces IL-6 expression. A pharmaceutical composition for preventing or treating inflammatory skin diseases comprising the strain of claim 1, its lysate, culture medium, or an extract of the culture medium as an active ingredient. A health functional food composition comprising the strain of claim 1, a lysate thereof, a culture medium, or an extract of the culture medium.

Images